A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
← catalyst calendarNCT06161025 · readout in 559 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
860estimated
Sites
164
Countries
Australia, Brazil, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-27 | actual | When the study began enrolling |
| Primary completion | 2028-02-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Cancer
Interventions
- Drug: R-DXd — also filed as DS-6000a
- Drug: Paclitaxel
- Drug: Topotecan
- Drug: PLD — also filed as Pegylated Liposomal Doxorubicin
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
measured From date of randomization to data cut off, up to 18 months
Progression-free Survival (PFS) Based on BICR Assessment (Part B)
measured From date of randomization to data cut off, up to 26 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed